-
InnoCare and Keymed Jointly Announce First Subject Dosed in Clinical Trial of CCR8 Monoclonal Antibody ICP-B05
PharmaSources
February 24, 2023
InnoCare Pharma and Keymed Biosciences that the first subject has been dosed in clinical trial of ICP-B05.
-
Malaysian Genomics to Offer World's First DNA-Driven Fertility Test
Pharmasources
February 24, 2023
Group in strategic collaboration with Divine Genes to offer genetic tests related to reproductive health in Malaysia and overseas.
-
CPHI China opens for international partnering after China rises in CPHI Index
PharmaSources.com
June 08, 2022
CPHI & P-MEC China opens its online international partnering platform as pharmaceutical and biopharmaceutical industries in the country report strong underlying conditions and see increases in all categories of the most recent CPHI Pharma Index.
-
Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology
PharmaSources
April 17, 2024
Company is targeting pancreatic cancer pain with advanced nerve detection and treatment technology
-
InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area’s Early Access Program
PharmaSources
January 23, 2024
The early access program of the Greater Bay Area allows designated medical institutions in the area to access drugs and medical devices that have been approved by regulatory authorities for marketing in Hong Kong or Macao.
-
ProBioGen Was Granted a New Patent for DirectedLuck® Transposase Technology
B3C newswire
January 17, 2024
ProBioGen announced today that the Japan Patent Office (JPO) issued the first patent for the company’s DirectedLuck® technology.
-
InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-332 Meet Primary Endpoint in Patients with Atomic Dermatitis
PharmaSources
January 17, 2024
InnoCare Pharma announced today that phase II clinical study results of novel TYK2 inhibitor ICP-332 met primary endpoint in adult patients with moderate-to-severe atopic dermatitis.
-
Calypso Enters into Agreement to Be Acquired by Novartis
B3C newswire
January 08, 2024
Calypso is a European biotech translating Interleukin-15 biology into medical breakthroughs by developing CALY-002, an anti-IL-15 monoclonal antibody, for an array of autoimmuneindications
-
Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics
B3CNewswire
January 05, 2024
On January 4, 2024, Beijing time, Allorion Therapeutics announced that it has entered into a transfer agreement with Avenzo Therapeutics, Inc. (Avenzo) of the United States
-
InnoCare to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PharmaSources
December 28, 2023
InnoCare Pharma announced today that Dr. Jasmine Cui, Co-founder, Chairwoman and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference, at 08:30 AM, January 10, 2024, U.S.